Long-Acting Injectable Regimen Demonstrated Comparable Safety And Efficacy To Oral HIV Therapy
The findings of the study were presented in an oral abstract presentation at the Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle, Washington.
The 48-week results of the Antiretroviral Therapy as Long-Acting Suppression (ATLAS) study indicate that the regimen of monthly injectable cabotegravir/rilpivirine is noninferior to continued 3-drug oral antiretroviral (ART) therapy in adults with virologically suppressed HIV-1 infections.
The findings of the study were presented in an oral abstract presentation at the Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle, Washington. Contagion® spoke exclusively to Susan Swindells, MBBS, who presented the findings at the meeting.
“The study was partnered by a study called FLAIR, which was a similar design in patients who were just starting anti-HIV therapy," said Dr Swindells, an investigator on the study. "They had very similar results: high levels of suppressions in both arms, patients liked it, and both studies went extremely well.”
ATLAS was a phase 3, open-label, multicenter study, which enrolled 616 participants who had HIV-1 RNA <50 c/mL for > 6 months without virologic failure on oral ART regimens of either 2 nucleoside reverse transcriptase inhibitors plus 1 integrase strand transfer inhibitor (NRTI + ISTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), or a protease inhibitor (PI).
A version of this article was originally published by Contagion. Visit ContagionLive.com to view the full article.
